SecBot SecBot
PRESS-RELEASE ·Filed Nov 8, 2026

MLYS

Mineralys Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed8d 8h ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The sustained efficacy and safety data de-risks the upcoming PDUFA decision on December 22, 2026. Monitor the FDA advisory committee meeting (if any) and the final label for commercial potential.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$15.81
T+0 close · Nov 8, 2026 · via day close
Latest settled
−8.10%
T+5 · $14.53
Vs SPY
−6.40%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $15.81entry
  2. T+1 · 7d ago −1.83%α −1.47% · $15.52
  3. T+5 · 18h ago −8.10%α −6.40% · $14.53
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mineralys Therapeutics presented long-term data from the Transform-HTN open-label extension trial of lorundrostat at AHA 2026, showing a sustained 17.8 mmHg reduction in systolic blood pressure at 48 weeks with 56% of participants achieving blood pressure below 130 mmHg. The FDA review of lorundrostat is ongoing with a PDUFA target date of December 22, 2026, and the data strengthens the safety and efficacy profile ahead of the decision.

Key Facts

  • Lorundrostat demonstrated a 17.8 mmHg reduction in AOSBP from Launch-HTN baseline to Week 48 (p<0.0001)
  • 56% of participants achieved AOSBP below 130 mmHg at Week 48
  • 92% of participants completed 48 weeks of follow-up; serious adverse events in 4.3% (0.3% treatment-related)
  • FDA PDUFA target date for lorundrostat is December 22, 2026
  • Results presented at AHA Scientific Sessions 2026 in a late-breaking oral session

Financial Impact

Positive late-stage clinical data supports potential FDA approval for a drug targeting a large hypertension market; no financial figures disclosed in the release.

Risk Factors

  • FDA may issue a Complete Response Letter (CRL) on CMC or other grounds despite positive clinical data
  • Commercial adoption depends on label, pricing, and competition from existing antihypertensives
  • Company is pre-revenue and dependent on successful approval and launch

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398023

Track record

35 reports on MLYS

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 8, 20268d ago Press Release Bullish 6/10 Viewing Entry $15.81 Now $14.53 −8.10% settles Dec 8
  2. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
  3. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
  4. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
  6. Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
  7. Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
  8. Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
  9. Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
  10. Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
Showing 10 of 35

US Market Status

Market Closed · Opens in 8h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 8, 2026